BioCryst Pharmaceuticals-2026-JPM.pdf

《BioCryst Pharmaceuticals-2026-JPM.pdf》由会员分享，可在线阅读，更多相关《BioCryst Pharmaceuticals-2026-JPM.pdf（23页珍藏版）》请在三个皮匠报告上搜索。

1、CONFIDENTIAL&PROPRIETARYBioCryst Pharmaceuticals,Inc.J.P.Morgan Healthcare ConferenceJ.P.Morgan Healthcare ConferenceJanuary 12,2026ForwardForward-looking statementslooking statements2This presentation contains forward-looking statements,including statements regarding,among other things,preliminary,

2、unaudited results and future results,performance or achievements,expectations regarding pipeline development,including timing of clinical trial results,expectations regarding BioCrysts growth and expenses,the expected benefits of BioCrysts acquisition of Astria(the“Merger”)and BioCrysts ability to r

3、ecognize the benefits of the Merger,expected Merger consideration,the anticipated financial impact of the Merger,BioCrysts or the combined companys performance following the Merger,including future financial and operating results,anticipated approval and commercialization of navenibart,pharmaceutica

4、l research and development,such as drug discovery,preclinical and clinical development activities and related timelines,and expected HAE portfolio revenue growth and addressable market,anticipated benefits,performance,and competitive positioning of,and market size for,navenibart and BCX17725,potenti

5、al best-in-class or first-in-class profile of product candidates(including navenibart and BCX17725),expectations regarding ORLADEYO peak revenue,and BioCrysts plans,objectives,expectations,intentions,growth strategies and other statements that are not historical facts.These statements involve known

6、and unknown risks,uncertainties and other factors which may cause BioCrysts actual results,performance,or achievements to be materially different from any preliminary,unaudited results and future results,performance,or achievements expressed or implied by the forward-looking statements.These stateme